Growth Metrics

Pfizer (PFE) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $121.2 billion.

  • Pfizer's Retained Earnings rose 7.52% to $121.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $121.2 billion, marking a year-over-year increase of 7.52%. This contributed to the annual value of $116.7 billion for FY2024, which is 137.55% down from last year.
  • As of Q3 2025, Pfizer's Retained Earnings stood at $121.2 billion, which was up 7.52% from $117.6 billion recorded in Q2 2025.
  • Over the past 5 years, Pfizer's Retained Earnings peaked at $131.1 billion during Q2 2023, and registered a low of $95.2 billion during Q2 2021.
  • Moreover, its 5-year median value for Retained Earnings was $118.4 billion (2023), whereas its average is $116.4 billion.
  • Its Retained Earnings has fluctuated over the past 5 years, first skyrocketed by 2153.12% in 2022, then tumbled by 947.23% in 2024.
  • Over the past 5 years, Pfizer's Retained Earnings (Quarter) stood at $103.4 billion in 2021, then rose by 21.53% to $125.7 billion in 2022, then decreased by 5.81% to $118.4 billion in 2023, then fell by 1.38% to $116.7 billion in 2024, then rose by 3.79% to $121.2 billion in 2025.
  • Its Retained Earnings stands at $121.2 billion for Q3 2025, versus $117.6 billion for Q2 2025 and $119.6 billion for Q1 2025.